An interventional study of Pancreatic MRI in Prevalence of Pancreas Adenocarcinomas, sponsored by Centre Hospitalier Saint Joseph Saint Luc de Lyon. Completed at 9 sites in France. Open to participants aged 40 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-01-13.
Sponsored by Centre Hospitalier Saint Joseph Saint Luc de Lyon · Not applicable, Interventional, and Diagnostic
Pancreatic adenocarcinoma is the 4th leading cause of cancer in the USA. Its incidence is increasing both in France and in Europe, whereas all the other cancers are decreasing in Europe. Moreover, its seriousness is still high, with a mortality rate higher than the average incidence. The aim of PAPAFA study is to assess the prevalence of the pancreatic anomalies which can be revealed thanks to imaging, for patients having a 1st degree pancreatic adenocarcinoma familial history. This could allow detection of lesions which are less than 10 mm long, and improve the dark prognostic of this pathology.
2,004 studies on the registry are indexed under Adenocarcinoma; 374 are open to participants now.
This study's enrollment of 200 is above the median of 45 across 1,553 interventional studies indexed under Adenocarcinoma.
Browse Adenocarcinoma studies →Centre Hospitalier Saint Joseph Saint Luc de Lyon is the lead sponsor of 20 studies on the registry; 8 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Pancreatic MRI in the 6 months following the first consultation
Procedure: Pancreatic MRI
Pancreatic MRI in the 6 months following the first consultation
Number of patients for whom the MRI and/or the echo endoscopy has shown a parenchymatous or ductal pancreatic anomaly
For every patients who will have a pancreatic MRI detecting an anomaly, the echo endoscopy will be done. A cytology of the lesion from the echo endoscopy will be done for the solid lesions and for the indetermined cystic lesions (that is to say, the lesions which don't meet the literature set criteria for serous kyst or intraductal papillary and mucinous tumor of the pancreas) ; which is usually done in health care.
Time frame: six months after the last inclusion
Number of patients for whom the MRI has brought to light a parenchymatous and/or ductal pancreatic anomaly
Time frame: six months after the last inclusion
Number of patients for whom the echo endoscopy has brought to light a parenchymatous and/or ductal pancreatic anomaly
Time frame: six months after the last inclusion
Height of the lesions
Time frame: six months after the last inclusion
Correlation between the data from the MRI and those from the echo endoscopy
Time frame: six months after the last inclusion
Localisation of the lesions
Time frame: six months after the last inclusion
Number of lesions
Time frame: six months after the last inclusion
Aspect of the lesion (solid and/or liquid)
Time frame: six months after the last inclusion
This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Saint Joseph Saint Luc de Lyon